LAM Therapeutics Inc. Report issue

For profit Phase 1
Founded: Guilford CT United States (2013)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2015
NCT02594384
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

LAM Therapeutics | Lam Therapeutics Inc.

Active Ingredients

Drugs in Phase 1 Trials (2)

apilimod mesylate (1 trial)

lam-003 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Lymphoma (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 2